In the past 12‑18 months the Modafinil market has accelerated through a series of strategic moves that reshape its competitive landscape. NeuroHealth Inc. announced a partnership with Cognizant Pharma to co‑develop a once‑daily extended‑release formulation, targeting corporate wellness programs. Meanwhile, Apex Therapeutics completed the acquisition of SomniTech for $210 million, consolidating generic manufacturing capacity and expanding its pipeline of sleep‑disorder assets. In Europe, the EMA granted a conditional approval for a novel transdermal patch, marking the first non‑oral delivery platform for Modafinil and opening new channels for off‑label use. On the regulatory front, the FDA issued updated guidance on off‑label prescribing, prompting tighter labeling and post‑marketing surveillance. Consumer behavior has also shifted, with a 22 % rise in tele‑health prescriptions driven by remote‑work fatigue. The latest funding round of $45 million secured by NeuroNova will fund a next‑generation micro‑tablet technology, positioning it for rapid market entry. These developments collectively signal a maturation of the Modafinil industry trends, with an emphasis on diversified delivery systems, consolidated supply chains, and digital health integration, setting the stage for sustained growth through 2027.
